Oligoasthenoteratozoospermia. Male infertility
Conditions
Interventions
Intervention 1: Intervention group: They will take one 250 mg S.cerevisiae yeast capsule containing 200 micrograms of organic selenium daily orally with meals for 3 months. Organic selenium will be pr
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: An infertile married man with idiopathic oligoasthenoteratozoosperm for at least one year Age 20 to 40 years No problem in wife fertility Non-addiction to alcohol and substance abuse
Exclusion criteria
Exclusion criteria: ?Azospermia Infectious disease and anatomical abnormalities of the genital tract Varicocele-related infertility History of pelvic surgeries or need to do so Cancer, liver and gallbladder diseases, diabetes, thyroid disorders, kidney failure, uncontrolled blood pressure, cerebral hemorrhage, retinal hemorrhage, unilateral testicular atrophy Abnormal karyotype History of receiving chemotherapy drugs, corticosteroids, anticoagulants, testosterone, anti-androgens Taking any chemical or herbal medicine specific to infertility during the project and the previous three months BMI>=30
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Semen parameters (number, morphology, motility). Timepoint: Baseline and 12 weeks after the intervention. Method of measurement: To calculate the number of live sperm, morphology and motility, a light microscope with a magnification of 1000× will be used.;Serum levels of androgens (total testosterone, free testosterone and dehydroepiandrosterone. Timepoint: Baseline and 12 weeks after the intervention. Method of measurement: Using ELISA method by monobind kits.;Sexual function score. Timepoint: Baseline and 12 weeks after the intervention. Method of measurement: BSFI: Brief Sexual Function Inventory.;Sex quality of life score. Timepoint: Baseline and 12 weeks after the intervention. Method of measurement: Sexual Quality of Life-M: SQOL-M. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy rate. Timepoint: 12 weeks after the intervention. Method of measurement: Follow-up for up to two months after the intervention and quantitative Beta-hCG testing if necessary.;Side effects. Timepoint: During and after the intervention. Method of measurement: Questionnaire.;Satisfaction with medication. Timepoint: During and after the intervention. Method of measurement: Satisfaction rate questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTabriz University of Medical Sciences
Tabriz University of Medical Sciences
Outcome results
None listed